Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department

Not Applicable

Completed

• Conditions: Opiate Addiction
• Interventions: Behavioral: Brief Negotiation Interview (BNI); Drug: Buprenorphine Initiation

• Registration Number: NCT00913770
• Lead Sponsor: Yale University

Brief Summary

Patients with heroin and prescription opioid dependence are at increased risk for adverse health consequences and often utilize the Emergency Department (ED) as their source of medical care. Screening, brief intervention and referral to treatment has been effective in decreasing high risk behaviors such as alcohol and tobacco use, and unsafe sexual practices. The data on the effectiveness of brief interventions with opioid dependence is limited. This prospective, randomized controlled trial of opioid dependent subjects (N=360) will compare two models of brief intervention with a control condition. ED patients with opioid dependence will be randomized to either: (1)Screening, Brief Intervention with a Facilitated Referral to Treatment (SBIRT); (2) Screening, Brief Intervention with ED initiated Buprenorphine Treatment (SBI+Bup); or (3) standard care (SC) which includes a handout detailing substance abuse treatment centers in the area. The primary outcome will be self-reported engagement in formal substance abuse treatment at 30 days, verified by contact with the treatment program. Other outcomes measured at 30 days, 2, 6 and 12 months include changes in opioid use (self-report and urine toxicology analysis), HIV risk behaviors, and health care service utilization. The three interventions will also be compared on their cost-effectiveness. We will test the hypotheses that SBI+Bup will be superior to SBIRT and SC, and SBIRT will be superior to SC in (1)increasing the proportion of patients engaged in formal substance abuse treatment at 30 days; (2) reducing illicit opioid use; (3) reducing HIV risk behaviors; and (4) reducing health care service utilization. In addition, we hypothesize that the societal costs of SBI+Bup, per number of days of opioid abstinence, will be cost effective relative to SBIRT or SC; and that SBIRT will be cost effective relative to SC. Data analyses will be conducted on the intention to treat sample of randomized patients. This study, conducted by a research team with extensive experience evaluating brief interventions and treatments for opioid dependence, will be unique in its: (1) comparison of two models of brief intervention with standard care; (2) inclusion of an ED initiated treatment arm; (3) use of manual-guided interventions with systematic assessment of adherence and competence; and (4)collection of detailed cost data to help guide future healthcare policy.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2008-09
• Study First Submitted: 2009-06-01
• Study First Submitted QC: 2009-06-03
• Study First Posted: 2009-06-04
• Primary Completion: 2013-08
• Study Completion: 2014-12
• Results First Submitted: 2015-05-11
• Results First Submitted QC: 2015-05-11
• Results First Posted: 2015-05-28
• Status Verified: 2020-03
• Last Update Submitted: 2020-03-12
• Last Update Posted: 2020-03-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 329

Inclusion Criteria

• Patients who present to the adult ED at Yale-New Haven Hospital (YNHH) who are:

  1. 18 years or older,
  2. meet criteria for opioid dependence as measured by the Mini-SCID, and
  3. have a positive urine toxicology for opiates.

Read More

Exclusion Criteria

• Inability to read or understand English
• Currently receiving formal substance abuse treatment
• Current suicide or homicidal risk
• Current psychotic disorder
• Life-threatening or unstable medical or psychiatric condition requiring hospital admission
• Unable to provide 2 phone contact numbers
• Unwilling to be randomized and/or follow up as per study protocol, including release of information to assess treatment engagement at 30-days
• Requiring opioid agonist medication for a pain-related diagnosis (contraindication to buprenorphine)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
SBIRT	Brief Negotiation Interview (BNI)	Screening, Brief Intervention and Facilitated Referral to Treatment
SBI+Bup	Brief Negotiation Interview (BNI)	Screening, Brief Intervention and Buprenorphine initiation
SBI+Bup	Buprenorphine Initiation	Screening, Brief Intervention and Buprenorphine initiation

Primary Outcome Measures

Name	Time	Method
Self-reported Engagement in Formal Substance Abuse Treatment at 30 Days (Verified by Contact With the Treatment Program)	30 days post randomization	Defined as enrollment and receiving formal addiction treatment on the 30th day following randomization. This is assessed by direct contact with facility, clinician, or both.

Secondary Outcome Measures

Name	Time	Method
Days of Self-reported Illicit Opioid Use in the Past 7 Days	30 days post randomization

Trial Locations

Locations (2)

Yale University; 🇺🇸 New Haven, Connecticut, United States

Yale University School of Medicine; 🇺🇸 New Haven, Connecticut, United States